
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseases Despite FDA approval nearly a decade …